Kotoe Katayama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kotoe Katayama has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Seiya Imoto
Division of Health Medical Intelligence, Human Genome Center, The Institute of Medical Science The University of Tokyo Tokyo Japan
3 shared publications - Ayako Maeda-Minami
Faculty of Pharmaceutical Sciences, Tokyo University of Science, Tokyo, Japan
2 shared publications - Eiichi Tahara
Department of Japanese Oriental (Kampo) Medicine, Oriental Medical Center, Iizuka Hospital, 3-83 Yoshio-cho, Iizuka, Fukuoka 920-8505, Japan
2 shared publications - Hideki Mima
Center for Research and Development of Higher Education, University of Tokyo, 7-3-1 Hongou, Bunkyo-ku, Tokyo 113-0033, Japan
2 shared publications - Hiroaki Hikiami
Shikino Care Center, 480 Washikitashin, Takaoka, Toyama 933-0071, Japan
2 shared publications - Kenji Watanabe
Center for Kampo Medicine, Keio University School of Medicine, Tokyo, Japan
2 shared publications
Latest Publications
- Open Access
- 30 May 2022
- Published by MDPI AG in Current Oncology
- Vol. 29 (6) , 3911-3921
Trop-2 in Upper Tract Urothelial Carcinoma
Trophoblast cell surface antigen 2 (Trop-2, encoded by TACSTD2) is the target protein of sacituzumab govitecan, a novel antibody-drug conjugate for locally advanced or metastatic urothelial carcinoma. However, the expression status of Trop-2 in upper tract urothelial carcinoma (UTUC) remains unclear. We performed immunohistochemical analysis of 99 UTUC samples to evaluate the expression status of Trop-2 in patients with UTUC and analyze its association with clinical outcomes. Trop-2 was positive in 94 of the 99 UTUC samples, and high Trop-2 expression was associated with favorable progression-free survival (PFS) and cancer-specific survival (p = 0.0011, 0.0046). Multivariate analysis identified high Trop-2 expression as an independent predictor of favorable PFS (all cases, p = 0.045; high-risk group (pT3≤ or presence of lymphovascular invasion or lymph node metastasis), p = 0.014). Gene expression analysis using RNA sequencing data from 72 UTUC samples demonstrated the association between high TACSTD2 expression and favorable PFS (all cases, p = 0.069; high-risk group, p = 0.029). In conclusion, we demonstrated that Trop-2 is widely expressed in UTUC. Although high Trop-2 expression was a favorable prognostic factor in UTUC, its widespread expression suggests that sacituzumab govitecan may be effective for a wide range of UTUC.
- 30 May 2022
- Published by MDPI AG in Current Oncology
- Vol. 29 (6) , 3911-3921
Open AccessTrop-2 in Upper Tract Urothelial Carcinoma
Trophoblast cell surface antigen 2 (Trop-2, encoded by TACSTD2) is the target protein of sacituzumab govitecan, a novel antibody-drug conjugate for locally advanced or metastatic urothelial carcinoma. However, the expression status of Trop-2 in upper tract urothelial carcinoma (UTUC) remains unclear. We performed immunohistochemical analysis of 99 UTUC samples to evaluate the expression status of Trop-2 in patients with UTUC and analyze its association with clinical outcomes. Trop-2 was positive in 94 of the 99 UTUC samples, and high Trop-2 expression was associated with favorable progression-free survival (PFS) and cancer-specific survival (p = 0.0011, 0.0046). Multivariate analysis identified high Trop-2 expression as an independent predictor of favorable PFS (all cases, p = 0.045; high-risk group (pT3≤ or presence of lymphovascular invasion or lymph node metastasis), p = 0.014). Gene expression analysis using RNA sequencing data from 72 UTUC samples demonstrated the association between high TACSTD2 expression and favorable PFS (all cases, p = 0.069; high-risk group, p = 0.029). In conclusion, we demonstrated that Trop-2 is widely expressed in UTUC. Although high Trop-2 expression was a favorable prognostic factor in UTUC, its widespread expression suggests that sacituzumab govitecan may be effective for a wide range of UTUC.
- 1 March 2020
- Published by Elsevier in Complementary Therapies in Medicine
- Vol. 49, 102353
Discrimination of prediction models between cold-heat and deficiency-excess patterns
- 1 March 2020
- Published by Elsevier in Complementary Therapies in Medicine
- Vol. 49, 102353
Discrimination of prediction models between cold-heat and deficiency-excess patterns
- 1 August 2019
- Published by Elsevier in Complementary Therapies in Medicine
- Vol. 45, 228-233
Prediction of deficiency-excess pattern in Japanese Kampo medicine: Multi-centre data collection
- 1 August 2019
- Published by Elsevier in Complementary Therapies in Medicine
- Vol. 45, 228-233
Prediction of deficiency-excess pattern in Japanese Kampo medicine: Multi-centre data collection